Catalent has the broadest range of technologies and solutions to overcome developmental and bioavailability challenges, and to enhance product performance.
Catalent is the leading global provider of advanced drug delivery technologies and development solutions for drugs, biologics, and consumer health products. The company has over 80 years’ experience serving the pharmaceutical industry, and proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable product supply.
Catalent’s solutions include analytical, pre-formulation and formulation technologies and expertise, and with the recent addition of spray dry dispersion specialist Pharmatek, it now offers further early development capabilities and the most comprehensive toolkit of bioavailability enhancing technologies. Catalent produces over 70 billion oral, sterile, biologic, and inhaled doses each year, for clients across five continents.
Built on its experience in early phase development, which has seen the company support more than 500 INDs, Catalent has extended the scope of its multi-award winning OptiForm® Solution Suite. This integrates multiple tools and services to deliver customised development programmes that provide innovators with a data-driven, key milestone approach and a thorough analysis of important drug molecule characteristics at each stage, including consideration of downstream processing and optimal dose design for the intended patient group, to improve the chances of success in both the clinic and beyond.
Catalent. More products. Better treatments. Reliably supplied.™
PostEra Expands Pfizer Partnership with AI Lab and ADC Collaborations
January 8th 2025The AI Lab was launched almost exactly three years ago and has produced several programs so far, at least one of which achieved its first scientific stage gate 40% faster than the teams originally forecasted.